For Heart Disease Patients With A History Of Heart Attacks And Strokes, Ticagrelor Is Used With Low-Dose Aspirin To Help Prevent Their Heart Attacks And Strokes

Ticagrelor is readily absorbed from the gut, with a 36% bioavailability, and reaches its peak concentration after around 1.5 hours. AR-C124910XX, the major metabolite, is promptly produced via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring. Ticagrelor plasma concentrations are slightly higher (12-23%) in the elderly, women, Asian ethnic groups, and patients with mild hepatic impairment. They are lower among those who identify as "black" and in those with significant renal impairment.

These discrepancies are not deemed clinically meaningful. Concentrations in Japanese persons are 40% greater than in Caucasians, or 20% higher after body weight correction. The medication has not been evaluated in patients with severe hepatic impairment. Because of its reversible method of action, Ticagrelor is known to function faster and for a shorter period of time than clopidogrel. This means it must be taken twice a day rather than once, which reduces compliance, but its effects are more immediately reversible, which might be advantageous before surgery or if side effects develop.

Read More- http://latestcmiblogs.weebly.com/article/in-people-with-a-history-of-heart-disease-ticagrelor-is-used-along-with-low-dose-aspirin-to-prevent-heart-attacks-and-strokes